

Characterising adults unvaccinated for COVID-19 in Scotland

By August 10, 2022, 3,497,208 of the 4,439,078 (79%) adults living in Scotland had received three doses of a COVID-19 vaccine.¹ However, a proportion of the adult population remains unvaccinated (defined as no record of any vaccine) and susceptible to severe COVID-19 outcomes. Characterising this population can help understand gaps in vaccine coverage, determinants of vaccine hesitancy and support targeted public health messaging. Unlike the vaccinated population, on whom information is gathered at point of vaccination, current estimates of the unvaccinated population are calculated using GP records. This is however complicated as GP records can include people who have moved out of Scotland with estimates suggesting that GP records contain a population that is 8% higher than National Records of Scotland population estimates.² We used data from linked national health records to estimate the number and describe the characteristics of adults living in Scotland with no record of any COVID-19 vaccination.

This analysis was performed using the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) platform.³ This is a national COVID-19 surveillance platform using anonymised individual patient-level records from all general practices in Scotland (N=940), deterministically linked to multiple datasets recording morbidity, mortality, virology, vaccination, and prescribing (Appendix 1). Linkage was performed using a unique identifier for each resident in Scotland registered with a GP.

The EAVE II cohort includes all individuals registered with a Scottish GP as of March 1, 2020, including those who have subsequently left Scotland without informing their GP. To eliminate people no longer living in Scotland, we defined unvaccinated individuals as those without COVID-19 vaccination records who had any interaction with the National Health Service (NHS) Scotland since Jan 1, 2019. We used the EAVE II cohort at a cut-off date of Dec 8, 2020 (start of the UK's vaccination programme). Appendix 2 outlines the process followed to identify the unvaccinated population. We excluded individuals who died of any cause before the cut-off date and those recorded as having left Scotland. As those aged <18 years were only recently invited for vaccination, analysis was restricted to adults aged ≥ 18 years.

This yielded 4,712,810 individuals recorded as eligible for COVID-19 vaccination. Linkage of vaccine eligibility data with COVID-19 vaccination records identified 872,268 (18.5%) eligible individuals without vaccination records. Amongst those, 88,820 had documented reasons for non-vaccination, including: "Immunization contraindicated", "Immunization consent not indicated", "Reason for non vaccination", "Generally unwell" and "Vaccine refused by patient".⁴ Immunization contraindicated was recorded as reason for nearly one-fifth of all unvaccinated individuals. Laboratory records identified 278,194 individuals with no vaccination record who were tested at least once for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcriptase-polymerase chain reaction (RT-PCR) since the start of the pandemic. Non-hospital-based prescription records identified 440,327 individuals with no vaccination record who had been prescribed medication of any description since January 1, 2019. A further 302,689 individuals had interacted with the unscheduled care pathway (NHS24, Out of Hours GP

37 consultations, and/or Scottish Ambulance Service), whilst 13,751 had at least one hospital admission
38 according to the Scottish Morbidity Records (SMR) and Rapid Preliminary Inpatient Data (RAPID)
39 datamart. In total there were 271,815 individuals with no record in any of the above data sources and who
40 did not have a vaccination record.

41 In total, 600,453 eligible individuals aged ≥ 18 years were identified as having no record of any COVID-19
42 vaccination in Scotland and at least one contact with NHS Scotland since Jan 1, 2019. We then excluded
43 those who had died since the start of the vaccination programme, and those for whom “Immunization
44 contra-indicated” was recorded as the reason for non-vaccination. On August 10, 2022, our methodology
45 identified 536,316 individuals with no record of any COVID-19 vaccination.

46 There were a similar proportion of males and females in this unvaccinated cohort, with similar age
47 distribution across both sexes (Table 1). The mean age was 50.1 years. Most unvaccinated people lived in
48 urban settings and the largest proportion of unvaccinated individuals (29.0%) resided in areas ranked “most
49 deprived 20% of the Scottish population” by the Scottish Index of Multiple Deprivation (SIMD).

50 Based on GP records, the majority (60.0%) of individuals were not known to have any co-morbidities,
51 whereas 16.3% were recorded as having three or more co-morbidities. The most reported co-morbidities
52 were chronic respiratory disease (15.9%), hypertension (11.0%) and depression (12.8%).

53 Nearly one-quarter (24.6%) of the unvaccinated were prescribed medications for conditions relating to the
54 central nervous system (CNS), with more than one-third of this group (37.4%) prescribed anti-depressants.

55 Multivariable logistic regression modelling was used to determine the factors most likely to predict COVID-
56 19 vaccination. Male sex, deprivation, living in large urban areas, being prescribed medication for CNS
57 disorders and having more than three comorbidities were most associated with unvaccinated status, though
58 individuals with specific co morbidities such as hypertension, diabetes and chronic respiratory disease were
59 more likely to be vaccinated.

60 Previous UK data have reported on inequalities of COVID-19 vaccination coverage, with considerably
61 lower uptake among certain groups.⁵ It is notable that increasing age and presence of comorbidities are
62 among the most recognised risk factors for COVID-19 mortality,⁶⁻⁸ but despite this those with substantial
63 number of comorbidities remained at increased risk of being unvaccinated.

64 The limitations of our approach include a lack of ethnicity data, which is important given known ethnic
65 variations in vaccine uptake.⁹ Whilst minimising false inflation of the unvaccinated denominator, some
66 unvaccinated individuals will have had no recent interaction with the healthcare system and, consequently,
67 remain undetected by our approach. Unvaccinated people may also be less likely to have health seeking
68 behaviour, reducing the chance of being detected through this method.¹⁰ Further, some individuals may
69 have been vaccinated outside of Scotland, which was not captured in our analysis. Determining those
70 vaccinated abroad will improve future estimates of unvaccinated populations

71 In summary, this national analysis has found that even after accounting for possible over-inflation of
72 population size a sizeable proportion of the adult Scottish population remains unvaccinated. We have also
73 identified predictors of being unvaccinated, which can help with formulating revised national vaccination
74 strategy.

75 (1000 words)

76 Safraj Shahul Hameed, Elliott Hall, Zoe Grange, Christopher Sullivan, Sharon Kennedy, Lewis D. Ritchie,
77 Utkarsh Agrawal, Colin R. Simpson, Syed Ahmar Shah, Igor Rudan, Colin McCowan, Josephine L K
78 Murray, Chris Robertson and Aziz Sheikh

79 aziz.sheikh@ed.ac.uk

80

81 Public Health Scotland, Glasgow, UK (SSH, EH, ZG, CS, SK, JLKM); Centre of Academic Primary Care,
82 University of Aberdeen, Aberdeen, UK (LR); School of Medicine, University of St Andrews, St Andrews,
83 UK (UA, CM); Usher Institute, School of Health, Wellington Faculty of Health, Victoria University of
84 Wellington, Wellington, New Zealand (CRS); University of Strathclyde and Public Health Scotland,
85 Glasgow, UK (CR);The University of Edinburgh, Edinburgh EH8 9AG, UK (SAS, IR, AS)

86

87 **Funding:** EAVE II is funded by the Medical Research Council with the support of BREATHE, the health data research hub for
88 respiratory health, which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered
89 through Health Data Research UK. Additional support was provided through Public Health Scotland and the Scottish Government
90 Director-General Health and Social Care. The research for this Correspondence is part of the Data and Connectivity National Core
91 Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and
92 Innovation. UA and CM acknowledge funding from Health Data Research UK (Measuring and Understanding Multimorbidity
93 using Routine Data in the UK – HDR-9006; CFC0110). The funding source had no involvement in data collection, study design,
94 data analysis, interpretation of findings, or the decision to publish this Correspondence.

95 **Contributorship:** SSH and EH contributed equally. AS and CR contributed equally.

96 **Conflict of interests:** AS and CR are members of the Scottish Government Chief Medical Officer's COVID-19 Advisory Group.
97 AS is a member of the NERVTAG Risk Stratification Subgroup and an unfunded member of AstraZeneca's COVID-19 strategic
98 consultancy group, the Thrombocytopenia Taskforce. CM reports research funding from the Medical Research Council, Health
99 Data Research UK, National Institute for Health Research, and the Scottish Chief Science Office. CR is a member of the Scientific
100 Pandemic Influenza Group on Modelling and the Medicines and Healthcare products Regulatory Agency COVID-19 Vaccine
101 Benefit and Risk Working Group. JLKM is a member of the COVID Scottish National Incident Management Team. All other
102 authors report no competing interests.

103 **Acknowledgements:** We thank Dave Kelly from Albasoft for support with making primary care data available, Iain McLaughlin
104 for help with the identification of the unvaccinated cohort and James Pickett, Wendy Inglis-Humphrey, Vicky Hammersley, Maria
105 Georgiou, Laura Gonzalez Rienda, Morna Coote, Amanda BurrIDGE, Amie Wilson, and Megan Gorman for project management
106 and administration support. We acknowledge the support of the EAVE II Patient Advisory Group for their help with interpretation
107 of findings and suggestions for dissemination and engagement

108 **References**

- 109 1. COVID-19 Daily Dashboard [Internet]. Public.tableau.com. 2022 [cited 15 August 2022]. Available
110 from: [https://public.tableau.com/app/profile/phs.covid.19/viz/COVID-](https://public.tableau.com/app/profile/phs.covid.19/viz/COVID-19DailyDashboard_15960160643010/Overview)
111 [19DailyDashboard_15960160643010/Overview](https://public.tableau.com/app/profile/phs.covid.19/viz/COVID-19DailyDashboard_15960160643010/Overview)
- 112 2. Stockton D. PHS reporting of cases, hospitalisations and deaths from COVID-19 by vaccine status –
113 Interpreting the data - Our blog - Public Health Scotland [Internet]. Publichealthscotland.scot. 2022
114 [cited 22 March 2022]. Available from: [https://publichealthscotland.scot/our-](https://publichealthscotland.scot/our-blog/2022/january/phs-reporting-of-cases-hospitalisations-and-deaths-from-covid-19-by-vaccine-status-interpreting-the-data/)
115 [blog/2022/january/phs-reporting-of-cases-hospitalisations-and-deaths-from-covid-19-by-vaccine-](https://publichealthscotland.scot/our-blog/2022/january/phs-reporting-of-cases-hospitalisations-and-deaths-from-covid-19-by-vaccine-status-interpreting-the-data/)
116 [status-interpreting-the-data/](https://publichealthscotland.scot/our-blog/2022/january/phs-reporting-of-cases-hospitalisations-and-deaths-from-covid-19-by-vaccine-status-interpreting-the-data/)
- 117 3. Simpson CR, Robertson C, Vasileiou E, McMenamin J, Gunson R, Ritchie LD et al. Early pandemic
118 evaluation and enhanced surveillance of COVID-19 (EAVE II): protocol for an observational study
119 using linked Scottish national data. *BMJ Open*, 10 (2020), Article e039097
- 120 4. UKHSA. COVID-19: the green book, chapter 14a. 2020 p. 35 [cited 11 August 2022]. Available from
121 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1057798/Greenbook-chapter-14a-28Feb22.pdf)
122 [/1057798/Greenbook-chapter-14a-28Feb22.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1057798/Greenbook-chapter-14a-28Feb22.pdf)
- 123
- 124 5. Perry M, Akbari A, Cottrell S, Gravenor M, Roberts R, Lyons R et al. Inequalities in coverage of
125 COVID-19 vaccination: A population register based cross-sectional study in Wales, UK. *Vaccine*.
126 2021;39(42):6256-6261.
- 127 6. Flook M, Jackson C, Vasileiou E, Simpson CR, Muckian MD, Agrawal U, et al. Informing the public
128 health response to COVID-19: a systematic review of risk factors for disease, severity, and mortality.
129 *BMC Infect Dis*. 2021 Apr 12;21(1):342.
- 130 7. Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in
131 patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis
132 of observational studies. *Aging Male*. 2020 Dec;23(5):1416-1424.
- 133 8. Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe
134 disease and mortality in COVID-19: A global systematic review and meta-analysis. *PLoS One*. 2021
135 Mar 4;16(3):e0247461.
- 136 9. Gaughan C, Razieh C, Khunti K, Banerjee A, Chudasama Y, Davies M et al. COVID-19 vaccination
137 uptake amongst ethnic minority communities in England: a linked study exploring the drivers of
138 differential vaccination rates. *Journal of Public Health*. 2022;. fdab400,
139 <https://doi.org/10.1093/pubmed/fdab400>
- 140 10. Glasziou P, McCaffery K, Cvejic E, Batcup C, Ayre J, Pickles K et al. Testing behaviour may bias
141 observational studies of vaccine effectiveness. *medRxiv* 2022. doi:10.1101/2022.01.17.22269450

142

Table 1 – Characteristics of Unvaccinated and Adjusted Odds Ratio for COVID-19 Vaccination

Characteristic	No (%)		Adjusted Odds Ratio (95% CI)
	Unvaccinated	Vaccinated	
	536316	3840542	
Sex			
Male	272362 (50.8)	1834025 (52.2)	1
Female	263954 (49.2)	2006517 (47.8)	1.20 (1.19 – 1.20) ***
Age			
18-29	172967 (32.2)	594900 (15.5)	1
30-39	127544 (23.8)	573402 (14.9)	1.31 (1.30 -1.32) ***
40-49	76663 (14.3)	591062 (15.4)	2.16 (2.14 – 2.18) ***
50-59	52390 (9.8)	739572 (19.2)	3.86 (3.81 -3.90) ***
60-69	36354 (6.8)	625955 (16.3)	4.46 (4.40 – 4.52) ***
70-79	29106 (5.4)	462098 (12.0)	3.99 (3.93 – 4.05) ***
80+	41292 (7.7)	253553 (6.6)	1.64 (1.61 – 1.66) ***
SIMD			
1 – Most deprived	155547 (29.0)	715940 (18.6)	1
2	117163 (21.8)	751771 (19.6)	1.29 (1.28 – 1.31) ***
3	96772 (18.0)	768149 (20.0)	1.52 (1.50 – 1.53) ***
4	81996 (15.3)	797045 (20.7)	1.86 (1.84 – 1.88) ***
5 – Least deprived	75694 (14.1)	783932 (20.4)	2.20 (2.17 – 2.22) ***
Setting			
Large urban areas	229377 (43.5)	1258528 (33.0)	1
Other urban areas	174854 (33.2)	1431672 (37.5)	1.35 (1.34 – 1.36) ***
Accessible small town	40189 (7.6)	370703 (9.7)	1.33 (1.31 – 1.4) ***
Accessible rural	39853 (7.5)	362035 (9.5)	1.27 (1.26 – 1.29) ***
Remote small town	21817 (4.1)	193717 (5.1)	1.32 (1.30-1.34)
Remote rural	21082 (3.4)	200182 (5.2)	1.26 (1.24 –1.28)
Comorbidities			
0	321822 (60.0)	1966549 (51.5)	1
1	80452 (15.0)	748260 (19.6)	0.99 (0.98 – 1.00)
2	71907 (13.4)	622614 (16.3)	0.91 (0.90 – 0.92)
3-4	46680 (13.4)	398878 (10.4)	0.67 (0.66-0.69)
5+	15455 (2.9)	80432 (2.1)	0.33 (0.32 – 0.34) ***
Risk factors			
Chronic respiratory diseases	85129 (15.9)	636940 (16.7)	1.33 (1.31 – 1.35)
Depression	68965 (12.8)	487925 (12.8)	0.97 (0.96 – 0.98)
Hypertension	59051 (11.0)	707928 (18.5)	1.33 (1.31 – 1.35) ***
Chronic heart diseases	33762 (6.3)	281783 (7.4)	0.10 (0.98 – 0.14)
Diabetes	25946 (4.8)	270545 (7.1)	1.24 (1.22 – 1.26) ***
Medication			
Central nervous system	112641 (24.6)	649716 (19.1)	0.80 (0.79 – 0.81) ***
Cardiovascular system	45107 (9.8)	553681 (16.3)	1.13 (1.12 – 1.14) ***
Respiratory	31860 (6.9)	240811 (7.1)	1.01 (0.10 – 1.02)

144
145
146
147
148
149
150

SIMD – Scottish Index of Multiple deprivation; Large Urban Areas - Settlements of 125,000 people and over; Other Urban Areas - Settlements of 10,000 to 124,999 people; Accessible Small Towns - Settlements of 3,000 to 9,999 people, and within a 30 minute drive time of a Settlement of 10,000 or more; Remote Small Towns - Settlements of 3,000 to 9,999 people, and with a drive time of over 30 minutes to a Settlement of 10,000 or more; Accessible Rural Areas - Areas with a population of less than 3,000 people, and within a 30 minute drive time of a Settlement of 10,000 or more; Remote Rural Areas - Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a Settlement of 10,000 or more.

Chronic respiratory diseases - Includes Asthma, COPD and Extrinsic allergic alveolitis. *** -P < <0.001